Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapyMark Brantly, Terence R. Flotte, James M. Wilson et al.|Proceedings of the National Academy of Sciences|2009Cited by 322
Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Serotype 2 <i>α</i> 1-Antitrypsin (AAT) Vector in AAT-Deficient AdultsMark Brantly, Terence R. Flotte, L. Terry Spencer et al.|Human Gene Therapy|2006Cited by 175
728. Safety and Bioactivity of rAAV2-hAAT in alpha-1 Antitrypsin-Deficient Patients in a Phase I Clinical TrialMark Brantly, Terence R. Flotte, Terry Spencer et al.|Molecular Therapy|2006Cited by 0
Clinical Evaluation of a Recombinant Adeno-Associated Virus (rAAV) Alpha-1 Antitrypsin (AAT) Gene Therapy Vector.Jeff Chulay, Terence R. Flotte, Mark Brantly et al.|Unknown|2009Cited by 0
Phase I Trial of Intramuscular Injection of a Recombinant Adeno-associated Virus Serotype 2 ? <sub>1</sub> -Antitrypsin (AAT) Vector in AAT-Deficient AdultsMark Brantly, Terence R. Flotte, L. Terry Spencer et al.|Human Gene Therapy|2006Cited by 0